Friday, 24 Jan 2020

You are here

Hyperuricemia Increases Risk of Diabetes, Death and CV Disorders in Hypertensive Patients

While hyperuricemia is linked to gout and many of the elements that make up the metabolic syndrome, it's not so clear that hyperuricemia is an independant risk factor for hypertension, diabetes, cardiovascular outcomes, etc.

A systematic review and metanalysis has shown that hyperuricemia slightly raises the risk of cardiovascular diseases and diabetes in patients with established hypertension.

Analysis of 17 cohort studies revealed that hyperuricemia significantly correlated with cardiovascular diseases in hypertensive patients (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.13–2.03), all-cause mortality (HR, 1.12; 95%CI, 1.02–1.23), and diabetes (HR, 1.84; 95% CI, 1.02–3.30) but not with stroke (HR, 0.85; 95%CI, 0.57–1.27).

Hyperuricemia and risk of cardiovascular disease in hypertensive patients.

Hyperuricemia and risk of cardiovascular disease in hypertensive patients


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.